The global congestive heart failure (CHF) treatment devices market was valued at USD 5.6 billion in 2024 and is projected to reach USD 8.2 billion by 2030, growing at a CAGR of 6.7% from 2025 to 2030. This growth is primarily fueled by technological advancements in devices such as ventricular assist devices (VADs) and artificial heart pumps, which significantly improve patient survival rates, quality of life, and post-treatment recovery. With cardiovascular diseases continuing to be a leading cause of morbidity and mortality worldwide, the need for effective heart failure treatment solutions is rising steadily.

The degree of innovation in the industry is currently high, with continuous improvements in device technology. Ventricular assist devices, which support heart function in patients with severe heart failure, are becoming more compact, efficient, and durable. Similarly, artificial heart pumps are evolving to be less invasive, more energy-efficient, and safer for long-term use. Advancements in minimally invasive surgical techniques are also contributing to market growth, as they reduce hospital stays, lower complication risks, and enhance recovery times.

Ongoing research and development is a critical driver of progress in the sector. Companies are focusing on enhancing device efficiency, durability, and biocompatibility, as well as integrating smart monitoring capabilities. For example, in March 2024, Analog Devices, Inc. received FDA 510(k) clearance and launched its Sensinel Cardiopulmonary Management System, a compact, wearable, non-invasive device for remote monitoring of cardiopulmonary measurements. This technology is particularly beneficial in chronic disease management for conditions like heart failure, enabling early detection of complications and reducing the need for frequent hospital visits.

Key Market Trends & Insights:

• North America dominated the global CHF treatment devices market in 2024 with a 45.6% share, supported by advanced healthcare infrastructure, high awareness levels, and favorable reimbursement policies for cardiovascular treatments.
• Asia Pacific is emerging as the fastest-growing region, driven by the rising prevalence of cardiovascular diseases, large patient populations, and increased healthcare spending in countries such as China, Japan, and India.
• The implantable cardioverter defibrillators (ICDs) segment accounted for the largest revenue share of 34.3% in 2024, owing to their effectiveness in preventing sudden cardiac arrest in high-risk patients. The ventricular assist devices (VADs) segment is expected to record the fastest CAGR from 2025 to 2030, fueled by growing adoption as both a bridge-to-transplant solution and a destination therapy for patients ineligible for heart transplants.

Order a free sample PDF of the Congestive Heart Failure Treatment Devices Market Intelligence Study, published by Grand View Research.

Market Size & Forecast:

• 2024 Market Size: USD 5.6 Billion
• 2030 Projected Market Size: USD 8.2 Billion
• CAGR (2025-2030): 6.7%
• North America: Largest market in 2024

Key Companies & Market Share Insights:

Key companies in the industry actively pursue various strategic initiatives to enhance their market presence. These initiatives include investing in research and development to innovate and improve the properties of congestive heart failure treatment devices, which aims to achieve better clinical outcomes and enhance patient comfort. To meet the global market's diverse needs, these players focus on product diversification, offering various types of products suitable for congestive heart failure treatment.

Key Players

• Jarvik Heart Inc.
• ReliantHeart, Inc.
• Biotronik SE & Co. KG
• Berlin Heart GmbH
• Medtronic
• Boston Scientific Corp.
• Biotronik SE & Co. KG
• Abbott

Explore Horizon Databook – The world's most expansive market intelligence platform developed by Grand View Research.

Conclusion:

In conclusion, the global congestive heart failure treatment devices market is poised for steady growth, driven by technological advancements in VADs, artificial heart pumps, and remote monitoring solutions. With North America leading in market share and Asia Pacific showing the fastest growth, ongoing innovation, product diversification, and a focus on patient comfort will continue to shape the industry through 2030.